Reach Us +1 218 451 2974


Dasotraline: ’New kid on the Bloc’

Attention Deficit Hyperactivity Disorder is a common neuro developmental disorder that can cause significant academic, interpersonal and adaptive impairments. Despite the development of several pharmacological options in last few years, search for an agent that is efficacious, has sustained clinical effects and without risk of abuse, continues. The need for such as agent is particularly critical considering the current opioid crisis. Sunovion Pharmaceuticals recently seeked FDA approval for one such agent Dasotraline which is a dopamine, serotonin and nor epinephrine reuptake inhibitor after preliminary trials established efficacy in adults and children with ADHD and Binge eating disorder in adult. We conducted a thorough review of the preclinical and clinical trials of this drug and used the information to summarize its safety, efficacy and tolerability in comparison to currently approved ADHD medications.


Pankhuree Vandana

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
30+ Million Readerbase
Recommended Conferences
Flyer image
Abstracted/Indexed in
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Secret Search Engine Labs